OriGene Releases 1500 TrueMAB™ Monoclonal Antibodies
News Jan 24, 2011
OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity. Greater than 50% of all TrueMAB antibodies are validated for immunohistochemistry and for flow cytomtery applications.
Monoclonal antibodies have become invaluable tools for researchers developing diagnostic tests and novel therapeutics. In 2010, OriGene announced its commitment to build the world's largest monoclonal antibody facility capable of producing over 20,000 TrueMAB antibodies per year. Recently, OriGene has released its 1,500th monoclonal antibody and hybridoma cell line under the TrueMAB brand name.
"We are extremely pleased with OriGene's progress in achieving this significant milestone in less than a year. Our antibody performance and hybridoma development capabilities have uniquely positioned us as an instrumental partner for diagnostic and research assay development. We fully anticipate releasing 400-500 new mouse monoclonal antibodies per month by end of 2011 as we head towards our ultimate goal," commented Wei-Wu He, Ph.D., CEO & Chairman, OriGene Technologies.
TrueMAB antibodies and hybridoma cell lines from OriGene are generated using OriGene's large collection of full-length human proteins as primary antigens that have been affinity purified under native conditions to preserve natural protein conformations. As a result, TrueMAB antibodies provide high sensitivity and specificity for the recognition of native epitopes on the protein's natural conformational structure.
With the introduction of TrueMAB antibodies, each included with an over-expression control protein lysate, OriGene now provides higher quality and greater numbers of monoclonal antibodies for diagnostic and research applications.
All TrueMAB antibodies are routinely validated for critical applications such as immunohistochemistry, immunofluorescent staining, flow cytometry, immunoprecipitation, and Western blot analysis. The hybridoma cell lines are available for immediate licensing to partnering organizations.